India's Wockhardt Ltd. has received qualified infectious disease product (QIDP) status from the US Food and Drug Administration (FDA) for its zidebactam-based combination antibiotic WCK 6777 to treat complicated urinary tract infections and complicated intra-abdominal infections, taking to six the total number of its products with this special designation.
The agency grants QIDP status to drugs effective against a set of multi-drug resistant pathogens identified by the Centers for Disease Control, providing an incentive to companies for the development...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?